Global Erythropoietin Drugs Market to be Worth USD 10.39 Billion by 2021: Technavio

Technavio has published a new report on the global erythropoietin drugs market from 2017-2021. (Graphic: Business Wire)

???pagination.previous??? ???pagination.next???

LONDON--()--The global erythropoietin drugs market is projected to grow to USD 10.39 billion by 2021, according to Technavio’s latest report.

In this report, Technavio covers the market outlook and growth prospects of the global erythropoietin drugs market for 2017-2021. Based on application, the erythropoietin drugs market is segmented into end-stage renal disease, cancer, HIV, and wounds and neural disease.

The rising need for cost-effective treatment is driving the emergence of several biosimilars such as Bonocrit by Sandoz. These drugs are a very affordable means of effective treatment, which is leading more people to procure these drugs, thereby driving the growth of the market.

Technavio’s research study segments the global erythropoietin drugs market into the following regions:

  • EMEA
  • Americas
  • APAC

EMEA

EMEA is the largest regional segment of the global erythropoietin drugs market, responsible for almost 44% of the overall revenue. The region is set to showcase moderate growth rate, driven by the growth from countries such as the UK, Germany, Spain, France, and Italy,” says Sapna Jha, a lead analyst at Technavio for cardiovascular and metabolic disorder research.

The region represents 80% of the global biosimilars spending, which will add stimulus to the growth of the market. Nineteen biosimilar products are authorized in four molecule classes – human growth hormone, EPO, G-CSF, and tumor necrosis factor (TNF)-inhibitors.

Request a sample report: http://www.technavio.com/request-a-sample?report=57098

Technavio’s sample reports are free of charge and contain multiple sections of the report including the market size and forecast, drivers, challenges, trends, and more.

Americas

The patent expiry of drugs such as Epogen and Aranesp, combined with the establishment of a proper regulatory framework for biosimilar approval within the US are expected to be the major factors influencing the growth of the market segment over the forecast period. The US is one of the key revenue contributors to the erythropoietin drugs market in the Americas, where there are ample opportunities for the expansion of the market. The changing regulatory landscape and emerging healthcare reforms will drive the growth of the market segment.

APAC

APAC has a high potential for growth and remains a promising manufacturing hub for erythropoietin biosimilars, making it the fastest growing regional segment of the global erythropoietin drugs market. Also, the rising market penetration of the drugs will add significant revenue to the market,” says Sapna.

Countries such as Japan, Australia, India, South Korea, and China are expected to be the major revenue contributors to the market. Also, the rise in the number of initiatives undertaken by major vendors to assist patients in these countries is a significant contributor to the increase in sales in these regions.

The top vendors in the global erythropoietin drugs market highlighted in the report are:

  • F. Hoffmann-La Roche
  • Amgen
  • Johnson & Johnson
  • Kyowa Hakko Kirin

Browse Related Reports:

Become a Technavio Insights member and access all three of these reports for a fraction of their original cost. As a Technavio Insights member, you will have immediate access to new reports as they’re published in addition to all 6,000+ existing reports covering segments like cardiovascular devices, central nervous system, and in-vitro diagnostics. This subscription nets you thousands in savings, while staying connected to Technavio’s constant transforming research library, helping you make informed business decisions more efficiently.

About Technavio

Technavio is a leading global technology research and advisory company. The company develops over 2000 pieces of research every year, covering more than 500 technologies across 80 countries. Technavio has about 300 analysts globally who specialize in customized consulting and business research assignments across the latest leading edge technologies.

Technavio analysts employ primary as well as secondary research techniques to ascertain the size and vendor landscape in a range of markets. Analysts obtain information using a combination of bottom-up and top-down approaches, besides using in-house market modeling tools and proprietary databases. They corroborate this data with the data obtained from various market participants and stakeholders across the value chain, including vendors, service providers, distributors, resellers, and end-users.

If you are interested in more information, please contact our media team at media@technavio.com.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 630 333 9501
UK: +44 208 123 1770
www.technavio.com

Release Summary

The global erythropoietin drugs market is projected to grow to USD 10.39 billion by 2021, according to Technavio’s latest report.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 630 333 9501
UK: +44 208 123 1770
www.technavio.com